Detalles de la búsqueda
1.
Intratumoral Immunotherapy: Is It Ready for Prime Time?
Curr Oncol Rep
; 25(8): 857-867, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37129706
2.
Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.
Rheumatology (Oxford)
; 61(2): 775-780, 2022 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33836046
3.
Plasmacytoid pre-dendritic cells (pDC): from molecular pathways to function and disease association.
Semin Cell Dev Biol
; 86: 24-35, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29444460
4.
Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome.
Am J Hematol
; 99(7): 1427-1430, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642007
5.
Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.
Ann Rheum Dis
; 78(7): e67, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29858173
6.
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
J Immunother Cancer
; 12(5)2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38702147
7.
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.
J Immunother Cancer
; 12(4)2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38631710
8.
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.
Eur J Cancer
; 204: 114065, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38643707
9.
Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni Syndrome.
JCO Precis Oncol
; 8: e2400139, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38848519
10.
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.
JCO Precis Oncol
; 8: e2300631, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38815178
11.
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
Cancer Treat Rev
; 127: 102751, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38729086
12.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Eur J Cancer
; 205: 114075, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38733717
13.
Antibody drug conjugates in older patients: State of the art.
Crit Rev Oncol Hematol
; 193: 104212, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38007063
14.
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC.
Sci Adv
; 9(45): eadh0708, 2023 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37939189
15.
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Eur J Cancer
; 193: 113313, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748398
16.
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
Eur J Cancer
; 179: 28-47, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36473326
17.
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
JCO Precis Oncol
; 7: e2200583, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36862966
18.
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.
Cancer Discov
; 13(4): 858-879, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36669143
19.
Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers.
J Exp Clin Cancer Res
; 42(1): 333, 2023 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38057799
20.
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.
J Immunother Cancer
; 10(2)2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131864